For research use only. Not for therapeutic Use.
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer[1][2].
| Catalog Number | I041594 |
| CAS Number | 1629760-28-6 |
| Purity | ≥95% |
| Reference | [1]. Trail PA, et al. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018 Jan;181:126-142. [2]. Li F, et al. Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity[J]. Cancer Research, 2016, 76(14_Supplement): 2966-2966. |
